SCHEMBL6554801

SCHEMBL6554801

Cc1cc(CN)ccc1C(=O)N1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.51
HTT P42858 2/20 0.50
ACACB O00763 1/20 0.50
PLA2G7 Q13093 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
TSHR P16473 1/20 0.46
L3MBTL3 Q96JM7 1/20 0.46
KMT2A Q03164 5/20 0.44
ALDH1A1 P00352 7/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 4/20 0.44
MAPT P10636 3/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GLA P06280 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6556516 0.80 KLKB1 (0.44) HPGDHTTACACBL3MBTL1KMT2A
SCHEMBL3401840 0.80 HPGD (0.55) HPGDHTTACACBPLA2G7L3MBTL1
SCHEMBL4160200 0.79 HPGD (0.58) HPGDHTTL3MBTL1TSHRL3MBTL3
SCHEMBL7154181 0.79 CHEK1 (0.43) HPGDHTTACACBL3MBTL1KMT2A
SCHEMBL5070484 0.78 HPGD (0.54) HPGDHTTPLA2G7L3MBTL1TSHR
SCHEMBL10126579 0.78 HPGD (0.54) HPGDHTTL3MBTL1TSHRL3MBTL3
SCHEMBL24016907 0.78 KMT2A (0.60) HPGDHTTL3MBTL1TSHRL3MBTL3
SCHEMBL25710940 0.77 HPGD (0.68) HPGDHTTL3MBTL1TSHRKMT2A
SCHEMBL542082 0.77 HPGD (0.54) HPGDHTTPLA2G7L3MBTL1TSHR
SCHEMBL11454853 0.77 HPGD (0.54) HPGDHTTPLA2G7L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390357-A2 ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2004-02-25 EP disclosed
US-20020151534-A1 Antithrombotic compounds BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-10-17 US disclosed
WO-2002062778-A2 ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151534-A1 Antithrombotic compounds SERPINC1, PF4, F2 HPGD 569/4885HTT 452/4885ACACB 2861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.